VivoSim Labs, Inc. Common Stock (VIVS)

Price$1.50

Favorite Metrics

Price vs S&P 500 (26W)-56.20%

Price vs S&P 500 (4W)-21.93%

Market Capitalization$3.94M

All Metrics

Book Value / Share (Quarterly)$1.70

P/TBV (Annual)0.36x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-54.21%

Cash Flow / Share (Quarterly)$-4.07

Price vs S&P 500 (YTD)-19.22%

Gross Margin (TTM)100.00%

Net Profit Margin (TTM)-864.08%

EPS (TTM)$1.07

10-Day Avg Trading Volume0.07M

EPS Excl Extra (TTM)$1.07

Revenue Growth (5Y)-42.03%

EPS (Annual)$-1.70

ROI (Annual)-23.71%

Gross Margin (Annual)96.53%

Net Profit Margin (5Y Avg)-4293.21%

Cash / Share (Quarterly)$1.64

Revenue Growth QoQ (YoY)8.33%

ROA (Last FY)-16.98%

Revenue Growth TTM (YoY)16.39%

EBITD / Share (TTM)$-0.52

ROE (5Y Avg)-124.91%

Operating Margin (TTM)-8066.20%

Cash Flow / Share (Annual)$-4.99

P/B Ratio0.89x

P/B Ratio (Quarterly)1.06x

Net Income / Employee (Annual)$-0

EV / Revenue (TTM)-2.46x

Net Interest Coverage (TTM)-4.05x

ROA (TTM)-11.34%

EPS Incl Extra (Annual)$-1.70

Current Ratio (Annual)3.25x

Quick Ratio (Quarterly)2.15x

3-Month Avg Trading Volume1.14M

52-Week Price Return-9.58%

Revenue / Employee (TTM)$0

P/S Ratio (Annual)27.35x

Asset Turnover (Annual)0.01x

52-Week High$5.30

Operating Margin (5Y Avg)-5827.01%

EPS Excl Extra (Annual)$-1.70

26-Week Price Return-52.22%

Quick Ratio (Annual)3.04x

13-Week Price Return-25.25%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)2.44x

Enterprise Value$-0.35

Revenue / Share Growth (5Y)-21.94%

Asset Turnover (TTM)0.01x

Revenue / Employee (Annual)$0

Inventory Turnover (Annual)0.03x

Pretax Margin (Annual)-1726.39%

Cash / Share (Annual)$5.96

3-Month Return Std Dev171.70%

Gross Margin (5Y Avg)84.18%

Net Income / Employee (TTM)$-0

ROE (Last FY)-23.71%

Net Interest Coverage (Annual)-257.00x

EPS Basic Excl Extra (Annual)$-1.70

Receivables Turnover (TTM)4.81x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$1.07

Receivables Turnover (Annual)4.57x

ROI (TTM)-15.56%

P/S Ratio (TTM)27.73x

Pretax Margin (5Y Avg)-4292.57%

Revenue / Share (Annual)$0.10

Tangible BV / Share (Annual)$5.53

Price vs S&P 500 (52W)-39.41%

Year-to-Date Return-16.57%

5-Day Price Return-1.31%

EPS Normalized (Annual)$-1.70

ROA (5Y Avg)-81.92%

Net Profit Margin (Annual)-1727.78%

Month-to-Date Return5.59%

EBITD / Share (Annual)$-1.61

Operating Margin (Annual)-8761.11%

ROI (5Y Avg)-124.91%

EPS Basic Excl Extra (TTM)$1.07

P/B Ratio (Annual)0.36x

Inventory Turnover (TTM)0.03x

Pretax Margin (TTM)-862.68%

Book Value / Share (Annual)$5.53

Price vs S&P 500 (13W)-25.94%

Beta1.54x

Revenue / Share (TTM)$0.05

ROE (TTM)-15.56%

52-Week Low$1.25

Analyst Recommendations

Sep 2021

Oct 2021

Nov 2021

Dec 2021

2.29

Industry Peers — Biological Products(88)

Symbol	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
VIVSVivoSim Labs, Inc. Common Stock	27.73x	16.39%	100.00%	—	$1.50
AMGNAmgen Inc	5.13x	9.95%	73.30%	2.93%	$349.39
GILDGilead Sciences Inc	5.84x	2.40%	78.83%	133.64%	$138.55
ARGXargenx SE American Depositary Shares	12.46x	89.56%	150.91%	—	$828.35
BNTXBioNTech SE American Depositary Share	8.75x	-11.81%	84.21%	—	$102.12
BIIBBiogen Inc. Common Stock	2.60x	2.22%	75.69%	-18.77%	$176.02
MRNAModerna, Inc. Common Stock	11.02x	-39.93%	70.32%	—	$54.68
NBIXNeurocrine Biosciences Inc	4.49x	21.45%	98.18%	2.31%	$128.41
EXELExelixis Inc	4.96x	6.85%	96.39%	31.10%	$44.38
TECHBio-Techne Corp.	7.60x	1.64%	66.60%	-20.58%	$57.36
HALOHalozyme Therapeutics, Inc.	5.74x	37.55%	83.62%	22.89%	$66.64

About

VivoSim Labs Inc (formerly Organovo Holdings Inc) is a biotechnology company developing FXR314 for inflammatory bowel disease, validated through its proprietary 3D human tissue modeling platform. The company also generates revenue through liver toxicology screening services and drug safety profiling offerings for pharmaceutical and biotech clients across all stages of drug development.